Absence of Post-Transplantation Lymphoproliferative Disorder after Allogeneic Blood or Marrow Transplantation Using Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis
Open Access
- 19 July 2013
- journal article
- research article
- Published by Elsevier BV in Transplantation and Cellular Therapy
- Vol. 19 (10), 1514-1517
- https://doi.org/10.1016/j.bbmt.2013.07.013
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute (P01CA15396, P50CA96888, P30CA006973, T32HL7525)
This publication has 21 references indexed in Scilit:
- T-Cell–Replete HLA-Haploidentical Hematopoietic Transplantation for Hematologic Malignancies Using Post-Transplantation Cyclophosphamide Results in Outcomes Equivalent to Those of Contemporaneous HLA-Matched Related and Unrelated Donor TransplantationJournal of Clinical Oncology, 2013
- Monitoring and Preemptive Rituximab Therapy for Epstein-Barr Virus Reactivation after Antithymocyte Globulin Containing Nonmyeloablative Conditioning for Umbilical Cord Blood TransplantationTransplantation and Cellular Therapy, 2010
- Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantationBlood, 2009
- Preemptive Management of Epstein-Barr Virus Reactivation After Hematopoietic Stem-Cell TransplantationTransplantation, 2009
- HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation CyclophosphamideTransplantation and Cellular Therapy, 2008
- Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantationBlood, 2006
- The impact of monitoring Epstein–Barr virus PCR in paediatric bone marrow transplant patients: Can it successfully predict outcome and guide intervention?Pediatric Blood & Cancer, 2005
- Prompt versus preemptive intervention for EBV lymphoproliferative diseaseBlood, 2004
- Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell–depleted SCTBlood, 2001
- Depletion of EBV-infected cells in donor marrow by counterflow elutriation.1998